Altimmune, Inc., a clinical-stage biopharmaceutical company, focuses on the development of intranasal vaccines, immunomodulatory therapies, and treatments for liver disease. The company is headquartered in Gaithersburg, Maryland.
| Revenue (TTM) | 31,000 |
| Gross Profit (TTM) | $-66.69M |
| EBITDA | $-98.63M |
| Operating Margin | -318494.00% |
| Return on Equity | -28.90% |
| Return on Assets | -17.20% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.44 |
| Price-to-Book | 1.31 |
| Price-to-Sales (TTM) | 14808.44 |
| EV/Revenue | 10653.24 |
| EV/EBITDA | 11.93 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 420.00% |
| Shares Outstanding | $194.52M |
| Float | $164.34M |
| % Insiders | 0.43% |
| % Institutions | 77.98% |
Volatility is currently contracting
Altimmune NASDAQ: ALT executives outlined the company's strategy to build a liver-disease franchise around pemvidutide, a dual glucagon/GLP-1 agonist being developed for metabolic dysfunction-associated steatohepatitis, or MASH, alcohol use disorder, or AUD, and alcohol-related liver disease, or ALD.
GAITHERSBURG, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on Wednesday, September 30, 2026, at 10:30 a.m. ET.
Altimmune (ALT) reported earnings 30 days ago. What's next for the stock?
GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Thursday, September 10, 2026, at 9:30 a.m. ET.
ALT has moved pemvidutide into Phase III MASH testing, with supportive mid-stage data, regulatory backing and a 2029 readout ahead.
ALT's stronger cash position supports pemvidutide's MASH, AUD and ALD programs, but long timelines, funding needs and competition remain risks.
Altimmune posts a narrower Q2 loss. Its $519M in cash supports operations into 2029, while pemvidutide advances across liver and AUD studies.
Altimmune, Inc. (ALT) Q2 2026 Earnings Call Transcript
Altimmune NASDAQ: ALT said it has initiated patient enrollment in its global Phase III PERFORMA trial of pemvidutide for metabolic dysfunction-associated steatohepatitis, or MASH, while advancing plans for later-stage development in alcohol use disorder, or AUD.
Initiated global PERFORMA Phase 3 trial in MASH Reported positive topline data from RECLAIM Phase 2 trial in AUD Completed patient enrollment in RESTORE Phase 2 trial in ALD $519 million in cash, cash equivalents and investments as of June 30, 2026 Webcast to be held today at 8:30 a.m. ET GAITHERSBURG, Md.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ALT and any ticker you trade — then tracks every position and per-strategy win rate.
